Skip to main content
EuBiologics Co., Ltd. logo

EuBiologics Co., Ltd. — Investor Relations & Filings

Ticker · 206650 ISIN · KR7206650004 KO Manufacturing
Open in API
Filings indexed 425 across all filing types
Latest filing 2026-05-19 Regulatory Filings
Country KR South Korea
Listing KO 206650

About EuBiologics Co., Ltd.

http://eubiologics.com/eng/

EuBiologics Co., Ltd. is a biopharmaceutical company focused on improving global public health through the development and supply of safe and effective vaccines. The company specializes in preventative vaccines against global pandemics and emerging infectious diseases, with a key product being its oral cholera vaccine. In addition to its vaccine pipeline, EuBiologics provides Contract Research and Manufacturing Organization (CRMO) services. These services cover the development and GMP-compliant production of mammalian cell and microbial-derived biopharmaceuticals, including protein-based therapeutics and antibodies. The company is committed to technological innovation and adhering to international standards to address global health challenges.

Recent filings

Filing Released Lang Actions
단일판매ㆍ공급계약체결(자율공시)
Regulatory Filings Classification · 92% confidence The document is a voluntary regulatory disclosure of a single sales and supply contract (oral cholera vaccine to UNICEF), detailing contract value, term and conditions. It does not contain financial results, management discussion, capital issuance, share transactions, legal proceedings or ESG information. It is not announcing a report or an executive certification. Therefore it falls under the fallback category for miscellaneous regulatory announcements (RNS).
2026-05-19 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 94% confidence The document is the Korean “분기보고서” for the 17th fiscal period covering January 1 to March 31, 2026. It includes full financial statements, notes, management’s discussion and analysis, auditor opinion, and detailed corporate information, consistent with an interim/quarterly report rather than a brief earnings release or announcement. Therefore, it should be classified as an Interim / Quarterly Report. Q1 2026
2026-05-14 Korean
소속부변경
Regulatory Filings
2026-04-30 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Regulatory Filings
2026-04-30 Korean
[기재정정]타법인주식및출자증권취득결정
M&A Activity Classification · 75% confidence The document is a corporate disclosure announcing a decision by the company (유바이오로직스) to acquire an 80% stake in another company via a third-party allotment of new shares. This is clearly an acquisition of control (takeover/investment) rather than a routine financing for the company itself, a repurchase, or an issuance of its own shares. Among our categories, “M&A Activity (TAR)” best covers announcements and documents related to takeover bids or acquisitions of controlling interests in other entities.
2026-04-22 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 91% confidence The document is a Korean "주식등의 대량보유상황보고서" under the Capital Markets Act, detailing changes in large shareholdings, share counts, percentages, acquisition methods, and acquisition dates by a major shareholder and its related parties. This clearly matches a Major Shareholding Notification rather than an earnings release, management change, or other category.
2026-04-07 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.